Bank of America degrada el stock de Bluebird a "Neutral", reflejando las luchas financieras de la biotecnología. Bank of America downgrades Bluebird bio's stock to "Neutral," reflecting the biotech's financial struggles.

Bank of America redujo las acciones de Bluebird de "Comprar" a "Neutral", bajando el precio objetivo a $0.50. Bank of America downgraded Bluebird bio's stock from "Buy" to "Neutral," lowering the target price to $0.50. La compañía biotecnológica, que desarrolla terapias génicas para enfermedades genéticas graves, ha visto calificaciones mixtas de analistas. The biotech company, which develops gene therapies for severe genetic diseases, has seen mixed ratings from analysts. A pesar de las recientes rebajas, algunos como Barclays todavía lo califican de "sobrepeso". Despite recent downgrades, some like Barclays still rate it "Overweight." El stock de Bluebird bio cayó a $0,32, reflejando métricas financieras negativas como un margen neto negativo de 567,29%. Bluebird bio's stock fell to $0.32, reflecting negative financial metrics like a 567.29% negative net margin. Los inversores institucionales han incrementado sus participaciones en la empresa. Institutional investors have increased their stakes in the company.